Vera Therapeutics (VERA) Receivables - Accured (2023 - 2026)

Vera Therapeutics (VERA) has 4 years of Receivables - Accured data on file, last reported at $3.9 million in Q1 2026.

• Quarterly Receivables - Accured rose 8.98% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 million (up 8.98% YoY) and the FY2025 annual result came in at $3.3 million, down 12.93% from the prior year.
• Receivables - Accured grew to $3.9 million in Q1 2026, from $3.3 million in the prior quarter.
• In the past five years, Receivables - Accured ranged from a high of $4.2 million in Q2 2025 to a low of $512000.0 in Q4 2023.
• A 4-year average of $2.8 million and a median of $3.3 million in 2025 frame the typical range for Receivables - Accured.
• Annual changes were most pronounced in 2024 — Receivables - Accured soared 636.91% — and 2025, when it fell 12.93%.
• Tracing VERA's Receivables - Accured over 4 years: stood at $512000.0 in 2023, then soared by 636.91% to $3.8 million in 2024, then decreased by 12.93% to $3.3 million in 2025, then increased by 18.96% to $3.9 million in 2026.
• The last three Receivables - Accured figures came in at $3.9 million (Q1 2026), $3.3 million (Q4 2025), and $3.4 million (Q3 2025), per Business Quant data.